Passage Bio, Inc. (PASG) Stock Price & Analysis
Passage Bio, Inc. (PASG) rose 1.27% to USD 5.57 as of June 10, 2026 at 02:16 UTC, according to Nexqual real-time market data.
PASG last closed at USD 5.5; the session ranged USD 5.41–5.9 on volume of 27,518 shares. Market capitalization is $17.87M, with a 52-week range of USD 3.94–20 (NCM). Source: Nexqual, June 10, 2026 at 02:16 UTC.
Key Statistics (as of June 10, 2026 at 02:16 UTC)
| Price | USD 5.57 |
|---|---|
| Change | ▲ 1.27% (up) |
| Previous Close | USD 5.5 |
| Open | USD 5.61 |
| Day Range | USD 5.41 – 5.9 |
| 52-Week Range | USD 3.94 – 20 |
| Volume | 27,518 shares |
| Market Cap | $17.87M |
| Exchange | NCM |
Technical Analysis (PASG)
Nexqual's technical model rates PASG "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:16 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.73 (neutral) |
| vs SMA50 | Below (USD 6.54) |
| MACD | -0.09 (negative) |
Analyst Ratings (PASG)
Wall Street analysts rate PASG "None" based on 5 analysts, with a mean price target of USD 11.4 (range USD 7–23), per Nexqual as of June 10, 2026 at 02:16 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 11.4 |
| High Target | USD 23 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 1 / 4 / 0 |
Earnings (PASG)
| EPS Estimate | USD -2.48 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -4.09 vs est -2.8 ▼ miss |
| 2025-09-30 | USD -2.44 vs est -2.97 ▲ beat |
| 2025-06-30 | USD -2.96 vs est -4.15 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financials & Fundamentals (PASG)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -128.90% |
| Debt / Equity | 48.97 |
| Current Ratio | 1.73 |
| Total Cash | $33.34M |
| Total Debt | $5.75M |
| Free Cash Flow | $-13.15M |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financial Health Score (PASG)
Nexqual rates Passage Bio, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:16 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $33M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$31M |
| Efficiency | Critical — ROE -129%, ROA -38.4% |
Ownership (PASG)
| Insider Ownership | +0.41% |
|---|---|
| Institutional Ownership | +58.41% |
| Shares Outstanding | 3.21M |
| Float | 2.89M |
| Short % of Float | +4.74% |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Leadership (PASG)
Passage Bio, Inc. is led by William Chou (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:16 UTC.
| President, CEO & Director | William Chou (age 52) |
|---|---|
| Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer | Kathleen Borthwick (age 48) |
Major Backers & Investors (PASG)
Notable institutional backers of Passage Bio, Inc. include Lynx1 Capital Management Lp, Vestal Point Capital, LP, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 02:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lynx1 Capital Management Lp | 19.44% |
| Vestal Point Capital, LP | 9.51% |
| Renaissance Technologies | 4.17% |
| Eversept Partners, LP | 4.1% |
| Yiheng Capital Management, L.P. | 2.68% |
| Erste Asset Management GmbH | 2.66% |
| Ikarian Capital, LLC | 2.12% |
| Fidelity | 1.1% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.11% |
| Geode Capital | 1.29% |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
From Passage Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
- It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
- The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease.
- It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc | USD 1.9 | ▼ 3.55% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
| PLRX | Pliant Therapeutics, Inc. | USD 1.19 | ▲ 3.48% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 8 | ▲ 6.67% |
| ALEC | Alector, Inc. | USD 1.63 | ▼ 0.31% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:16 UTC. This page is informational and not investment advice.